Caelum Biosciences
is a New York-based biotechnology company that develops and commercializes drugs for the treatment of AL amyloidosis and hematologic disorders... Read moreCaelum Biosciences
is a New York-based biotechnology company that develops and commercializes drugs for the treatment of AL amyloidosis and hematologic disorders... Read more
News
Oct 07, 2021
The Business Journals: Philadelphia
Caelum Biosciences: AstraZeneca completes acquisition of Bordentown-based Caelum Biosciences
Oct 07, 2021
Pharmaceutical Business Review
Caelum Biosciences: AstraZeneca's Alexion concludes Caelum acquisition for $500m
Oct 01, 2021
The Business Journals: Philadelphia
Caelum Biosciences: Caelum Biosciences to be acquired by division of AstraZeneca in $150M deal
Sep 30, 2021
PMLiVE
Caelum Biosciences: AZ buys Caelum Biosciences for $500m
Sep 30, 2021
Equal Ocean
Caelum Biosciences: AstraZeneca acquires Caelum Biosciences overweight rare diseases business
Sep 29, 2021
MarketScreener
Caelum Biosciences: Fortress Biotech : Alexion Therapeutics exercises its option to purchase Caelum Biosciences (Form 8-K)
Jun 14, 2021
The Science Times
Caelum Biosciences: Caelum, Alexion Present Additional Data for CAEL-101 to Help Improve Cardiac, Renal Conditions
Jun 10, 2021
Acrofan
Caelum Biosciences: Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Associ
May 12, 2021
CompanyNews HQ
Caelum Biosciences: Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021
Mar 01, 2021
GlobeNewswire
Press Release: Caelum Biosciences : Caelum Biosciences Announces Collaborations with the Amyloidosis Advocacy Community and Support of Amyloidosis Awareness Month
Caelum Biosciences Competitors
1
2
3
4
5
6
7
8
9
10